Why David Schenkein Sold 13,000 Stock of Agios Pharmaceuticals, Inc. (AGIO)?; Vornado Realty Trust (VNO) Sentiment Is 1.05

Vornado Realty Trust is a publicly owned real estate investment trust. The company has market cap of $13.61 billion. The firm invests in the real estate markets of the United States. It has a 79.27 P/E ratio. It makes investments in commercial real estate properties to create its portfolio.

The Chief Executive Officer of Agios Pharmaceuticals Inc and firm’s insider David Schenkein unloaded 13,000 shares of the stock exchange listed company based on the stock price per share of $81.1 per share. The insider shares close to $1,054,218 US Dollars. This is not his first insider trade, in the last month, he unloaded another 13,000 shares worth $1,023,756 USD. David Schenkein has ownership of roughly 0.61% of Agios Pharmaceuticals Inc’s stock market capitalization or 350,854 shares. Considering the size of the sell, it is difficult to remain unseen.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.83 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals has $132 highest and $47 lowest target. $78.86’s average target is -6.38% below currents $84.23 stock price. Agios Pharmaceuticals had 44 analyst reports since July 23, 2015 according to SRatingsIntel. The company was maintained on Thursday, February 15 by JP Morgan. The rating was downgraded by Janney Capital to “Neutral” on Monday, June 26. As per Thursday, June 1, the company rating was maintained by Oppenheimer. Roth Capital maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Wednesday, August 5. Roth Capital has “Hold” rating and $114 target. RBC Capital Markets maintained it with “Buy” rating and $88.0 target in Wednesday, February 14 report. The firm has “Buy” rating by J.P. Morgan given on Monday, September 18. The firm has “Neutral” rating given on Friday, August 19 by BTIG Research. The company was maintained on Tuesday, June 6 by Cowen & Co. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by Oppenheimer on Tuesday, August 8. The rating was maintained by Cowen & Co on Tuesday, August 1 with “Buy”.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on May, 3. They expect $-1.60 earnings per share, down 2.56% or $0.04 from last year’s $-1.56 per share. After $-1.81 actual earnings per share reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -11.60% EPS growth.

Investors sentiment decreased to 1.21 in Q3 2017. Its down 0.83, from 2.04 in 2017Q2. It fall, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported. Bb Biotech Ag invested in 2.75M shares. Lazard Asset Mgmt Ltd Limited Liability Company has 0.01% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 52,659 shares. Parametric Port Assocs Limited Co accumulated 21,565 shares. State Common Retirement Fund holds 94,000 shares. Eaton Vance reported 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Prelude Cap Mgmt Limited Liability Company invested 0.03% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Whittier Commerce Of Nevada holds 140 shares. Employees Retirement Association Of Colorado has 6,505 shares. Platinum Investment Mngmt owns 35,800 shares. Capital World Investors has invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Goldman Sachs Grp has 0.02% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 932,156 shares. Cubist Systematic Strategies Ltd Liability Company holds 2,391 shares or 0.01% of its portfolio. Daiwa Sb Investments reported 3,311 shares or 0.05% of all its holdings. Bluecrest Capital Limited holds 0.02% or 7,498 shares in its portfolio. Pictet Asset Mgmt Limited, a United Kingdom-based fund reported 54,700 shares.

The stock increased 4.04% or $3.27 during the last trading session, reaching $84.23. About 389,441 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since March 6, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Since September 11, 2017, it had 0 insider buys, and 21 insider sales for $24.61 million activity. Schenkein David P had sold 80,000 shares worth $5.61 million on Wednesday, October 4. $284,380 worth of stock was sold by Cantley Lewis Clayton Jr. on Monday, October 16. Bowden Christopher had sold 2,000 shares worth $157,500. Biller Scott also sold $195,000 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. 2,050 shares were sold by Hoerter Steven L., worth $161,192 on Thursday, February 22. $161,250 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was sold by Alenson Carman.

The stock increased 1.25% or $0.83 during the last trading session, reaching $67.22. About 1.56M shares traded or 25.14% up from the average. Vornado Realty Trust (VNO) has risen 1.51% since March 6, 2017 and is uptrending. It has underperformed by 15.19% the S&P500.